BMSEED is a manufacturer of stretchable microelectrode array (sMEA) and cell stretcher technology. Our elastically stretchable MEAs remain electrically functional while being stretched, enabling real-time, high-resolution analysis of cell behavior under mechanical forces. This capability allows researchers to replicate the dynamic, biomechanical conditions found in the human body, offering a more accurate and comprehensive approach to disease/injury modeling and pre-clinical drug screening.
More than 9 in 10 drugs that enter clinical trials fail to receive FDA approval, costing pharmaceutical companies over $64B annually. A key reason for these failures is that many diseases are caused by a combination of genetic, environmental, and lifestyle factors, yet most research tools only perform a single function, thus focusing only on a single disease mechanism. To improve clinical trial success rates, diseases with multi-factorial causes must be studied using multi-functional assays to replicate real human conditions.
BMSEED’s core value proposition is to provide these multi-functional tools by combining stretchable MEA technology with advanced cell stretching systems. Our cell stretcher (MEASSuRE) integrates electrophysiology, mechanical stretching, and live cell imaging into one easy-to-use platform using stretchable MEAs. By improving the accuracy of pre-clinical screening, we aim to reduce the high costs of failed clinical trials by eliminating inadequate drug candidates early in the pre-clinical stages, and ultimately improving patient outcomes.
Website: www.bmseed.com
Phone: +1 (609) 532-9744
Email: [email protected]
-
所属行业
-
生物技术研究
-
规模
-
2-10 人
-
总部
-
Mesa，Arizona
-
类型
-
私人持股
-
创立
-
2012
-
领域
-
Biotechnology、Cell Stretching、Electrophysiology、Cell Imaging、MicroElectrode Arrays、Life Science Research、In Vitro Research、Mechanobiology、Traumatic Brain Injury、Spinal Cord Injury、Repeated Concussions、In-Situ, Real-Time Monitoring、Cardiac和hiPSC Maturation
